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Abstract
Background: Population-based estimates of HIV incidence in France have revealed that men who have sex with men (MSM)
are the most affected population and contribute to nearly half of new infections each year. We sought to estimate HIV
incidence among sexually active MSM in Paris gay community social venues.
Methodology/ Principal Findings: A cross-sectional survey was conducted in 2009 in a sample of commercial venues such
as bars, saunas and backrooms. We collected a behavioural questionnaire and blood sample. Specimens were tested for HIV
infection and positive specimens then tested for recent infection by the enzyme immunoassay for recent HIV-1 infection
(EIA-RI). We assessed the presence of antiretroviral therapy among infected individuals to rule out treated patients in the
algorithm that determined recent infection. Biomarker-based cross-sectional incidence estimates were calculated. We
enrolled 886 MSM participants among which 157 (18%) tested HIV positive. In positive individuals who knew they were
infected, 75% of EIA-RI positive results were due to ART. Of 157 HIV positive specimens, 15 were deemed to be recently
infected. The overall HIV incidence was estimated at 3.8% person-years(py) [95%CI: 1.5–6.2]. Although differences were not
significant, incidence was estimated to be 3.5% py [0.1–6.1] in men having had a negative HIV test in previous year and 4.8%
py [0.1–10.6] in men having had their last HIV test more than one year before the survey, or never tested. Incidence was
estimated at 4.1% py [0–8.3] in men under 35 years and 2.5% py [0–5.4] in older men.
Conclusions/ Significance: This is the first community-based survey to estimate HIV incidence among MSM in France. It
includes ART detection and reveals a high level of HIV transmission in sexually active individuals, despite a high uptake of
HIV testing. These data call for effective prevention programs targeting MSM engaged in high-risk behaviours.
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Introduction
Population-based estimates of HIV incidence in France have
revealed that incidence rates have declined in all major population
groups whereas it has remained steadily high since 2003 in men
who have sex with men (MSM) [1]. At the country level, MSM
contribute to nearly half of new infections each year. As in many
high income countries, these trends are observed against a
background of expanding uptake of highly active antiretroviral
therapy (HAART) [2,3].
In 2009, the Prevagay study surveyed a cross-sectional sample of
MSM attending commercial gay venues in Paris, which has the
largest gay community in France [4]. The collection of blood
specimens as part of the study made it possible to identify persons
seropositive for HIV and among them those who were recently
infected according to a biomarker assay. In the past 15 years
laboratory-based methods have been developed to estimate
incidence of HIV with a cross-sectional approach [5–6]. Still, as
with other concurrent approaches to estimate HIV incidence,
there are a number of potential sources of error and bias with the
biomarker approach [7]. The major problems identified include
the selection bias associated with the early testing of recently
infected persons as they are recruited in clinics or testing centers
[8]; the error associated with an improper estimation of the time
spent during recent infection [9]; the presence of ‘‘assay non-
progressors’’ patients that remain permanently into the recent
infection state [10]; and the perturbation introduced by advanced
HIV disease and antiretroviral therapy [11].
Here we report on a biomarker-based estimation of HIV
incidence in a sample of sexually active MSM that tries to address
these sources of error.
Methods
The Prevagay Survey
An anonymous cross-sectional survey (Prevagay) was conducted
in 2009 in a sample of 14 commercial venues in Paris gay
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methodology and characteristics of study participants have been
described previously [4].
In brief, during 56 interventions lasting each 4-hours, male
attendees were approached by trained fieldworkers and screened
for eligibility, which included being 18 years or older and history
of sex with another man in past 12 months. A refusal questionnaire
collecting age, self-reported HIV status and reason for refusal was
administered to those individuals declining to participate. After
giving informed consent, eligible attendees completed a self-
administered questionnaire and provided blood sample regardless
of self-reported HIV status. Questionnaire data provided infor-
mation on demographics and behavioral characteristics, compris-
ing self-reported HIV status, history of HIV testing and of sexually
transmitted infections. Sample collection consisted in a fingerstick
whole blood spotted on a filter paper card. The study protocol was
approved by the local Committee for the Protection of Persons
and the Data Protection Supervisory Authority.
Biological Analyses
HIV testing was performed on dried blood spot with a
combined immunoassay for detection of both p24 antigen and
HIV antibodies (Genscreen ultra HIV Ag-Ab; Biorad) by the
National Reference Laboratory for HIV (Tours, France). HIV
positive specimens were confirmed by Western blot and then
tested for recent infection by the enzyme immunoassay for recent
HIV-1 infection (EIA-RI) [12]. The performance of EIA-RI at
detecting recently acquired infection had been previously assessed
on new diagnoses reported to surveillance [13]. The assay had also
been calibrated and used to estimate population-based HIV
incidence in France [1]. Its mean RITA duration (the time period
from infection during which individuals are classified as positive,
indicating a recent infection) was estimated among 952 serial
measurements from 298 seroconverters at 0.492 year or 179.7
days [95%CI: 167.2–192.2]. The maximum RITA duration was 2
years. The false recent rate for EIA-RI, that is the proportion of
long-term (more than 2 years) infected patients who would test as
positive, was determined among 250 chronically infected patients
at 0.8% [0–3.1%] [1].
Detection of Antiretroviral Drugs
It has been shown that prolonged efficient antiretroviral
treatment increases the rate of false recent results of the EIA-RI
and therefore may lead to overestimate incidence [14]. To rule out
treated patients from incidence estimation, we assessed the
presence of antiretroviral drugs in EIA-RI positive samples.
Concentrations were determined using liquid chromatography
coupled with tandem mass spectrometry (UPLC-MS/MS, Acquity
UPLCH - Acquity TQDH ) as previously described [15] with a
slightly modified extraction for the adaptation to dried blood spots.
Since only diagnosed individuals could be on treatment, we tested
the presence of antiretroviral drugs among infected men aware of
their HIV status and detected as EIA-RI positive.
Statistical Methods
Because unsufficient quantity of blood impeded to perform drug
detection in some sample, multiple imputation by chained
equations was used to account for the uncertainty due to missing
data regarding use of antiretroviral drugs. HIV incidence rate and
its confidence interval were derived according to the estimator
described by McWalter and Welte [16].
The number R of recently infected individuals was obtained by
considering HIV infected men detected as EIA-RI positive and
who did not use antiretroviral treatment. The incidence rate I was
estimated by I ˆ=[R- e(P-R)/(1- e)]/(Nv) with v the mean RITA
duration, e the false recent rate, P the number of HIV positive
individuals and N the number of negative.
Results
Of 1578 men invited to participate, 917 (58%) accepted to
participate and 886 (56%) both completed the survey question-
naire and provided a blood specimen. Men who refused to
participate were not different from those willing to participate in
terms of age or self-reported HIV serostatus. Among the 886
MSM participants, 157 (18%) tested HIV positive among which
31 men (20%) were unaware of their HIV infection (table 1).
Most men (831/886=94%) reported having had an HIV test
prior to the survey and (557/886=63%) a test within the previous
year. Among men already tested, 3% were infected with HIV
without knowing it and among men never tested, 13% were found
to be HIV-infected.
EIA-RI testing indicated a recent infection (EIA-RI positive) for
28 (18%) of the 157 HIV-infected individuals. Respectively, 11
EIA-RI positive results were found among the 31 persons unaware
of their HIV infection and 17 among the 126 persons aware of
their infection (figure 1).
We detected the presence of antiretroviral drugs in 9 (75%) out
of 12 EIA-RI positive specimens from men aware of their infection
and who provided sufficient material. The other 5 specimens could
not be tested for drug use because of insufficient blood quantity in
the paper card. Accounting for the uncertainty due to missing data
in these 5 specimens on 100 imputed datasets, we estimated that
on average 15 [95%CI: 9–24] infected men out of 157 could be
considered as recently infected (EIA-RI positive and free of
treatment, cf. figure 1).
The overall HIV incidence was then estimated at 3.8% person-
years [95%CI: 1.5–6.2]. It tended to be higher in men under 35
years (4.1% person-years [0–8.3]) or in men having had their last
test more than one year before the survey or never tested (4.8%
person-years [0.1–10.6]), compared to older men (2.5% person-
years [0–5.4]) and men having had a test in previous year (3.5%
person-years [0.1–6.1]). Although none of the above differences
were statistically significant (p=0.24 when comparing age groups
and p=0.28 when comparing testing history).
Discussion
This is the first community-based study to estimate HIV
incidence among MSM in France. It reveals a very high level of
HIV transmission (3.8% person-years) relative to the estimates we
obtained from national case-based surveillance (1% person-years
in MSM [1]). While not directly comparable to our estimate, a
review of 24 studies reporting incidence estimates in urban MSM
from Europe, North America or Australia from 1995 to 2005
found a mean incidence rate of 2.5% person-years [17]. The
present study clearly shows that MSM attending gay venues in
Paris are at a very high risk of HIV infection with almost 18%
prevalence of HIV and a background of high-risk behaviors as
reported in the first description of the study: in the previous year,
35% of MSM declared at least one unprotected anal intercourse
with a casual partner, 51% had had more than 10 different sex
partners, and 18% reported having at least one sexually
transmitted infection [4] (a detailed analysis of behavioral results
is currently submitted by Velter et al.).
Another important finding from our study is that, although the
participants were frequently tested for HIV, as already reported
for the MSM population [18], it was not sufficient enough for this
population to be timely informed about their HIV status. This has
HIV Incidence in MSM in Paris
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attitudes towards partners. Particularly, in these surveyed venues,
our results underline a limitation of serosorting strategies as an
alternative to condom use for preventing infection [19].
A major strength of this study is that we could obtain a blood
specimen directly in venue sites. This was made possible by
dedicating an adequate space for blood draw with venue owners in
the preparation of the study. It allowed us to assess the HIV-
serostatus of the enrolled subjects, perform the test for recent
infection and also exclude treated individuals from the incidence
calculation. For this purpose, the use of dried blood spots proved
its convenience. Because of practical and financial advantages,
dried blood spots are now widely used for the collection of samples
for determination of circulating exposures of pharmaceuticals. In
the future, they might also be used to detect antiretrovirals in pre/
post-exposure prophylaxis in seronegative MSM.
Incidence assays are known to be sensitive to antiretrovirals and
the EIA-RI is no exception [14] [11]. In detecting antiretrovirals
to exclude potential false recent infection, we controlled this source
of error. Conversely, in a largely treated population as is the case
in France [20], when excluding treated individuals from the
incidence calculation, we could have faced the risk that the
Table 1. HIV testing history according to HIV serostatus and knowledge of it and estimated incidence rate in the Prevagay survey,
Paris 2009.
HIV testing history N HIV serostatus Incidence rate [95%CI]
Positive Negative in person-years
Knew they were
infected* Did not know
Tested in previous year 557 32 (5.7%) 19 (3.4%) 506 (90.8%) 3.5% [0.1–6.1]
Tested over 1 year ago 274 94 (34.3%) 5 (1.8%) 175 (63.9%) 4.8% [0.1–10.6]
Never tested 55 0 (0.0%) 7 (12.7%) 48 (87.3%)
Total 886 126 (14.2%) 31 (3.5%) 729 (82.3%) 3.8% [1.5–6.2]
*Persons already diagnosed with HIV at the time of the survey were not supposed to having been tested since their initial diagnosis.
doi:10.1371/journal.pone.0039872.t001
Figure 1. Algorithm used to determine the number of recently infected individuals.* * Recently infected individuals were defined by a EIA-
RI positive sample and the absence of antiretroviral treatment ** Average estimates of multiple imputation.
doi:10.1371/journal.pone.0039872.g001
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term non-progressors since they do not require treatment. It would
have therefore increased the risk of misclassification in recent
infection determination and thereby the risk of overestimating
HIV incidence. However, this level of misclassification due to long
term non-progressors is taken into account in the false recent rate,
which was determined in a treatment–naive population of
chronically infected individuals [1].
Another asset of the study relates to its cross-sectional design in
venues which allowed us to enrol and test individuals indepen-
dently of their time since HIV infection. As opposed to
recruitments of MSM in testing facilities, where persons may be
more likely to seek a test as a consequence of a recent risk or
symptoms of primary HIV infection or other sexually transmitted
infections, our incidence determination is not prone to such a test-
seeking bias [8,21].
The representativity of our study population must however be
discussed. The acceptance rate we obtained (58%) is comparable
to those obtained in similar cross-sectional collection of behavioral
data and biological samples in gay venues in Europe and Australia
[22–26]. However, only men who attended the surveyed venues
had the opportunity to participate. As a consequence, the
estimates for incidence can not apply for all MSM in Paris. As
there were no noticeable difference between men who participate
and those who refused, and also no significant difference between
participants in the Prevagay survey and those of a larger
behavioral survey conducted in 72 commercial venues in Paris
[27], our sample is hopefully representative of the venue
population.
In most industrialized countries, MSM are the most affected
population by HIV infection and incidence estimation at the
community level is crucial. Our study provides an example of
using biomarker-based methodology to estimate HIV incidence in
gay venues that includes the detection of antiretroviral drugs in
dried fluid spots. In the context of wide use of HAART, new
preventive strategies might not only expand their therapeutic use
but may also expand the use among negative as a prophylactic
strategy [28]. In that perspective, we emphasize the need to
include the detection of antiretroviral drugs in the algorithm to
detect recent infection.
With a detailed view of the level of HIV transmission and testing
behaviours among sexually active MSM in Paris, our study reveals
a high level of HIV incidence in the context of gay venues and that
one can not only rely on an intensive testing policy to control the
epidemics. These data also call for effective prevention programs
targeting MSM engaged in high risk behaviours.
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